Evaxion A/S American Depositary Share

Evaxion announced new preclinical data supporting its multi-component cytomegalovirus (CMV) vaccine candidate EVX-V1, which combines AI-discovered antigens with optimized established antigens. The data demonstrates potential to improve control of acute infection, latency, and viral reactivation. EVX-V1 represents a scalable strategy for rational ...

Evaxion A/S received the 2026 Prix Galien UK Award for Best Digital Health Solution for its AI-Immunology™ platform, which uses artificial intelligence to develop novel vaccine candidates for cancer and infectious diseases. This marks the company's second recognition from the Galien Prix Foundation in less than a year, validating the platform's...

Evaxion announced positive preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). The vaccine successfully expresses and secretes in human cells, drives specific immune responses across different human immune profiles, and induces targeted cell-killing. The company is preparing regulatory filings for c...

Evaxion A/S announced the promotion of Birgitte Rønø to serve as both Chief Scientific Officer and Chief Operating Officer, reflecting her extensive contributions to the company's operations and scientific expertise. The move is intended to enhance external engagement and strategy execution while strengthening the company's ability to communica...

Evaxion announced data demonstrating its AI-Immunology platform can identify endogenous retrovirus (ERV)-derived antigens for glioblastoma vaccine design, in collaboration with Duke University. The findings show ERVs as a novel antigen source that could overcome limitations from low mutational burden in brain cancer, with results to be presented ...